Recent Updates
Recently added Catalysts

Iterum Therapeutics plc

ITRM
Richly ValuedPharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$0.03
▼ -0.01 · -28.57%

Last traded Mar 31, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ITRM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.0352W HIGH $1.42
Volume
65.74 M
Value Traded
2.64 M
Short % Float
18.07%
-81.93%Week
-87.95%1 Month
-89.97%3 Month
-95.59%6 Month
-99.86%5 Year
-99.98%All Time

Cash Data

Unlock ITRM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.72 M
EPS (TTM)
-0.75
P/E Ratio
-
Ent. Value
26.45 M
Total Shares
53.31 M
Float Shares
51.77 M
Insiders
0.79%
Institutions
3.65%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every ITRM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ITRM Catalyst Timeline

Dated clinical, regulatory and corporate events for Iterum Therapeutics plc

Unlock the full ITRM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ITRM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-10-25Oral Sulopenem PDUFA Date ApprovedPDUFA
Unlock 2 more ITRM historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D20 / 100
Pipeline Score
$1M
Pipeline Value
$0M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.3x
rNPV / MCap
Iterum Therapeutics plc faces pipeline headwinds (20/100), with $324M risk-adjusted pipeline value, led by Sulopenem-Etzadroxil/Probenecid in Urinary Tract Infections (Phase 3), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2025; product lines: last four quarters to Sep 2025 (10-K and 10-Q)) Revenue $0.4M x 1.0 = $0M
ProductRevenuePrior periodChange
ORLYNVAH$0M--
Showing 0 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the ITRM pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ITRM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
sulopenem
Fast Track
uncomplicated urinary tract infectionsPhase 32024-01-30sulopenem success: 61.7%; augmentin success: 55.0%Read MoreIterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority tRead More
Scroll for more · summaries link to the source press release
Unlock every ITRM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ITRM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Dunne Michael W.DirectorBuy 6,000 241,001 held$0.37 11/18/2025
Unlock the full ITRM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ITRM

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in ITRM for Q2 2026.
Unlock every fund holding ITRM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ITRM
Shares held by hedge funds each quarter, and who bought or sold.

ITRM Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ITRM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ITRM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ITRM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ITRM ranks across every disease it competes in

Competitive Position is a premium feature
See how ITRM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ITRM News

About Iterum Therapeutics plc

9 employees iterumtx.com
Headquarters3 DUBLIN LANDINGS, DUBLIN 1, L2, D01 H104
Founded2015
BIOPHARMAWATCH ELITE PLUS
Trade the next ITRM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime